Itrax

Itraconazole, the active ingredient in Itrax, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of invasive and superficial fungal infections in adult patients, including serious mycoses, candidiasis and as well as dermatophyte skin infections under medical supervision and appropriate monitoring.

GNH USA supplies Itrax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance across the European Union and other markets.

Itrax (itraconazole) is employed to treat fungal infections that involve the systemic or cutaneous pathways.

- Systemic mycoses (e.g., blastomycosis, histoplasmosis, aspergillosis): Provides effective therapy for deep‑seated invasive fungal infections. - Candidiasis: Clears both mucosal and invasive Candida infections, reducing symptom burden. - Dermatophyte infections: Resolves skin and nail infections caused by dermatophyte fungi, promoting lesion healing.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Abdominal pain - Rash

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury - Congestive heart failure or worsening of existing heart failure - QT interval prolongation and cardiac arrhythmias

When prescribing Itrax, clinicians should observe several precautionary measures to minimize risk.

- Monitor liver function: obtain baseline tests and repeat periodically during therapy. - Assess cardiac status: avoid use in patients with existing heart failure or significant arrhythmias. - Avoid use in pregnancy: category C; discuss potential risks with the patient. - Review concomitant medications: identify agents that may interact via CYP3A4 metabolism. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Itrax interacts with several medicines through metabolic pathways and additive toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort): markedly reduce itraconazole exposure. - Other azole antifungals (e.g., ketoconazole): increase risk of hepatotoxicity when combined.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates such as certain statins, calcium channel blockers, and benzodiazepines: may have increased plasma levels. - Antacids, H2‑blockers, and proton‑pump inhibitors: can lower itraconazole absorption. - Warfarin: may potentiate anticoagulant effect and require INR monitoring.